SLC5A2 and metabolic dysfunction-associated steatohepatitis: This study was designed to examine the potential preventive effect of the SGLT2 inhibitor empagliflozin (EMPA) against Dexamethasone (DEXA)-induced NASH in <i>Wistar</i> rats.<h4>Methods</h4>NASH was induced by daily injection of DEXA (8 mg/kg/day, i.p.)from day 8-13.